Amarin’s CEO drops some hints on Vascepa sales
Amarin CEO John Thero used his Wednesday breakout session at the J.P. Morgan Healthcare Conference to not-so-subtly telegraph a stronger 2019 sales outlook for Vascepa than the company’s official guidance offered last week.
Thero, of course, can’t come out directly and say that Vascepa, Amarin’s heart drug derived from fish oil, will deliver significantly more than a 50 percent year-over-year increase to $350 million in 2019 sales. Like Fight Club, the first rule of sandbagging revenue guidance is not talking about sandbagging revenue guidance.
But during meetings with investors over three days here, and then on Wednesday during the breakout session, Thero dropped plenty of hints.
Read more.
Thero, of course, can’t come out directly and say that Vascepa, Amarin’s heart drug derived from fish oil, will deliver significantly more than a 50 percent year-over-year increase to $350 million in 2019 sales. Like Fight Club, the first rule of sandbagging revenue guidance is not talking about sandbagging revenue guidance.
But during meetings with investors over three days here, and then on Wednesday during the breakout session, Thero dropped plenty of hints.
Read more.
No hay comentarios:
Publicar un comentario